SAB BIOTHERAPEUTICS, INC. Revenues
SAB BIOTHERAPEUTICS, INC. (SABS) reported Revenues of $85.52 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-21.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2023-08-21
- SAB BIOTHERAPEUTICS, INC. revenues for the quarter ending 2023-06-30 was $85.52K, a 98.65% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. revenues for the quarter ending 2023-03-31 was $581.10K, a 95.08% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. revenues for the quarter ending 2022-06-30 was $6.35M.
- SAB BIOTHERAPEUTICS, INC. revenues for the quarter ending 2022-03-31 was $11.80M.
| Period end | Revenues 3 month | Revenues 6 month |
|---|---|---|
| 2023-06-30 | $85.52K 10-Q · filed 2023-08-21 | $666.62K 10-Q · filed 2023-08-21 |
| 2023-03-31 | $581.10K 10-Q · filed 2023-05-15 | |
| 2022-06-30 | $6.35M 10-Q · filed 2023-08-21 | $18.15M 10-Q · filed 2023-08-21 |
| 2022-03-31 | $11.80M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |